Welcome to our dedicated page for Ultragenyx Pharm news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharm stock.
Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported preliminary 2021 revenue for Crysvita of $191-$193 million, exceeding guidance, and Dojolvi revenue of $38-$40 million. For 2022, Crysvita is projected at $250-$260 million, a 33% increase, while Dojolvi is expected between $55-$65 million, reflecting 60% growth. The year-end 2021 cash position stands at approximately $1 billion. The company is focused on commercializing Evkeeza in Europe and advancing clinical programs for rare diseases.
ReCode Therapeutics announced the appointment of Shehnaaz Suliman as CEO and board member, effective immediately. Former CEO David Lockhart transitions to Chief Scientific Officer. Dr. Suliman, with over 25 years in drug development, previously led Alector and held key roles at Theravance and Roche. She aims to advance ReCode's pipeline of genetic medicines utilizing their selective organ targeting platform. The leadership change is anticipated to enhance growth and innovative therapeutics in the biopharmaceutical space.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has announced that CEO Emil D. Kakkis will present at the H.C. Wainwright BioConnect Conference on January 13, 2022, at 7:00 AM ET. The presentation will be available via live and archived webcast on the company's website for 90 days. Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases, with a portfolio aimed at addressing conditions with high unmet medical needs. The company emphasizes efficient drug development to deliver urgent therapies to patients.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and GeneTx Biotherapeutics announced that the first four patients in their Phase 1/2 study of GTX-102, a treatment for Angelman syndrome, have received multiple doses. No serious adverse events were reported, and preliminary assessments indicate early signs of clinical activity. The Data Safety Monitoring Board recommended dose escalation for Cohort 4. Initial improvements in clinical assessments are noted, with further data expected by mid-2022. GTX-102 aims to reactivate the paternal UBE3A allele, addressing symptoms of Angelman syndrome.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the 40th Annual JP Morgan Healthcare Conference on January 10, 2022, at 3:45 PM ET. The presentation will be accessible via a live webcast on the company's website, with a replay available for 90 days afterward. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, boasting a diverse portfolio aimed at high unmet medical needs. The company emphasizes efficient drug development to deliver safe and effective treatments urgently.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and GeneTx Biotherapeutics presented new data on GTX-102, an investigational treatment for Angelman syndrome, at the 2021 FAST Global Summit. The Phase 1/2 study included findings from initial patients, focusing on adaptive behavior scales and EEG readings, indicating potential effectiveness. Enrollment for treatment-naive patients has begun. GTX-102 targets the UBE3A gene, with no approved therapies available for the disorder, which affects 1 in 12,000 to 20,000 people globally. A further update is anticipated by year-end 2021.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has announced the first patient dosing in its Phase 1/2 clinical trial for UX053, an mRNA therapy aimed at treating Glycogen Storage Disease Type III (GSDIII). The trial aims to evaluate safety, tolerability, and efficacy in adults aged 18 and older, with the potential to be the first approved medicine for GSDIII. UX053 targets the deficiency in glycogen debranching enzyme, a condition affecting over 10,000 patients worldwide. The FDA and European Commission have granted Orphan Drug Designation for UX053.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Evercore ISI 4th Annual HealthconX Conference on December 1, 2021, at 12:10 PM ET. The presentation will be available via live and archived webcast on the company's website for 90 days. Ultragenyx is dedicated to developing therapies for serious rare and ultra-rare genetic diseases, with a focus on unmet medical needs. The management team emphasizes efficient drug development to deliver safe and effective treatments rapidly.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced impressive long-term data from Phase 1/2 trials at the ICIEM. For DTX401 in Glycogen Storage Disease Type Ia, mean daily cornstarch intake reduction reached 69.9%, with significant glucose control improvements observed over three years. DTX301 for Ornithine Transcarbamylase deficiency demonstrated durable metabolic stability, with responders stable up to four years post-treatment. Notably, no major adverse events were reported, signaling potential for enhanced patient quality of life.
Ultragenyx Pharmaceutical reported Q3 2021 revenues of $81.6 million, driven by $50.3 million from Crysvita, marking a 35% year-over-year increase. The company anticipates total Crysvita revenue for the year at the higher end of $180 million to $190 million. Dojolvi revenue surged by 176% to $10.7 million. However, operating expenses rose to $171.5 million, a 30% increase due to pipeline advancements, leading to a net loss of $73 million. Ultragenyx is poised for multiple clinical study initiations, aiming to expand its innovative therapies for rare diseases.